Arecor Therapeutics (LON:AREC) Stock Price Down 1.5% – Should You Sell?

by · The Cerbat Gem

Arecor Therapeutics plc (LON:AREC – Get Free Report)’s share price dropped 1.5% on Friday. The stock traded as low as GBX 81.25 and last traded at GBX 81.25. Approximately 1,465 shares traded hands during trading, a decline of 94% from the average session volume of 26,433 shares. The stock had previously closed at GBX 82.50.

Arecor Therapeutics Trading Down 1.5%

The company has a 50 day simple moving average of GBX 77.26 and a two-hundred day simple moving average of GBX 69. The company has a debt-to-equity ratio of 1.55, a quick ratio of 6.24 and a current ratio of 4.29. The firm has a market cap of £30.68 million, a PE ratio of 81.25 and a beta of -0.18.

Arecor Therapeutics (LON:AREC – Get Free Report) last announced its quarterly earnings data on Thursday, October 1st. The company reported GBX (8) earnings per share (EPS) for the quarter. Arecor Therapeutics had a positive return on equity of 3.75% and a negative net margin of 200.00%. Analysts expect that Arecor Therapeutics plc will post -0.35 EPS for the current fiscal year.

About Arecor Therapeutics

(Get Free Report)

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.

Featured Articles